Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Ranolazine on Major Adverse Cardiovascular Events in Subjects With a History of Chronic Angina Who Undergo Percutaneous Coronary Intervention With Incomplete Revascularization.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary)
- Indications Angina pectoris; Cardiovascular disorders
- Focus Registrational; Therapeutic Use
- Acronyms RIVER-PCI
- Sponsors Gilead Sciences
- 30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
- 13 Oct 2015 Primary endpoint has not been met. (Time from randomization to first occurrence of ischemia-driven revascularization or ischemia-driven hospitalization without revascularization)
- 13 Oct 2015 Results published online in the Lancet.